Clinical trial
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in…
NCT00459901 · Peter Kozuch, Other · Terminated
Key facts
| NCT number | NCT00459901 |
|---|---|
| Title | Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer |
| Official title | Phase II Trial of OSI-774 (Erlotinib, Tarceva™,) and Capecitabine for Patients With Previously Untreated Metastatic Colorectal Cancer |
| Lead sponsor | Peter Kozuch, Other |
| Collaborators | Hoffmann-La Roche Industry Genentech, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib and capecitabine |
| Enrollment | 13 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Apr 13, 2007 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: